Icatibant: 7 agencies, 2008–2021
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused icatibant: all 10 decisive outcomes across 6 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 12.3 years separate the first record, 29 Oct 2008 at HAS (France), from the most recent, 4 Feb 2021 at AOTMIT (Poland).
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2021; on this evidence the file is dormant.
4 distinct indication wordings are recorded for icatibant by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 12 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess icatibant, on 29 Oct 2008; AOTMIT (Poland) did not open a file until 4 Feb 2021 — an unusually long tail of 12.3 years between the earliest and latest system to look at it.
3 of the 7 agencies here assessed icatibant more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for icatibant.
The full ledger for icatibant reads 9 recommended, 1 other, 1 advice and 1 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 4 Feb 2021 | Firazyr reimbursement recommendation | recommended | source |
| HAS (France) | 25 Jul 2018 | Re-assessment of SMR and ASMR | SMR substantial · ASMR III | source |
| AWMSG (Wales) | 12 Jun 2018 | Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years a… | recommended (limited) | source |
| SMC (Scotland) | 7 May 2018 | Symptomatic treatment of acute attacks of hereditary angioedema in adolescents and children aged 2 years and older (with C1-esterase-inhibitor deficiency). | accepted | source |
| PBAC (Australia) | 2016 | Hereditary angioedema | The PBAC rejected the submission’s claim that the additional use of icatibant reported by … | source |
7 further decisions for icatibant, across 5 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- lanadelumab — same ATC class B06A — Other hematological agents
- exagamglogene autotemcel — same ATC class B06A — Other hematological agents
- berotralstat — same ATC class B06A — Other hematological agents
- garadacimab — same ATC class B06A — Other hematological agents
- conestat alfa — same ATC class B06A — Other hematological agents
- donidalorsen — same ATC class B06A — Other hematological agents
Coverage: 12 decisions for icatibant from 7 agencies, 2008 to 2021. Data to 7 Sep 2026. ATC class B06A — Other hematological agents. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.